Adnan Özçetin

Effects of depression and anxiety on quality of life of patients with rheumatoid arthritis, knee osteoarthritis and fibromyalgia syndrome

OBJECTIVE To measure the effects of depression and anxiety on quality of life (QoL) in patients with rheumatoid arthritis (RA), knee osteoarthritis (OA) and fibromyalgia syndrome (FMS). METHODS One hundred and fifty-four patients with RA, knee OA, and FMS who presented to the physical medicine and rehabilitation department were studied. For evaluation of the patients, Beck depression scale, Beck anxiety scale, and Short Form-36 were used. RESULTS Twenty-two per cent of patients (n = 34) were diagnosed with of RA, 52.6% (n = 81) knee OA and 25.3% (n = 39) FMS. Except for the subscales, of physical and emotional role, there were statistically significant differences among diagnostic groups in the rest of the SF-36 subscales. In the physical functioning subscale, the highest score was obtained in the fibromyalgia group and the lowest in the RA group (p < 0.001). However, in the bodily pain subscale, the lowest score was recorded in the fibromyalgia group (p = 0.019). In all diagnostic groups, the scores of SF-36 subscales were significantly low in patients who scored above the threshold value of Beck depression scale (p < 0. 001). A strong negative correlation was detected between scores of Beck anxiety scale and the scores of all SF36 subscales in patients with RA and knee OA. On the other hand, in patients with FMS, anxiety scores correlated negatively with only physical and somatic function scores of SF-36. CONCLUSION Quality of life is significantly low in patients with RA, knee OA and FMS, whose depression and/or anxiety scores are high. Therefore, these patients should be managed using a multidisciplinary approach including psychiatric support.

Low-dose venlafaxine-associated liver toxicity in chronic hepatitis

1. Haire W, Herbst SE. The use of alteplase (t-PA) for the management of thrombotic catheter dysfunction. Guidelines from a Consensus Conference of the National Association of Vascular Access Networks. Nutrition Clin Pract 2000;15:265-75. 2. Haire W, Atkinson J, Stephens L. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a doubleblinded, randomized trial. Thromb Haemost 1994;72:543-7. 3. Deitcher SR, Fesen MR, Kiproff PM, Hill PA, Li X, McCluskey ER, et al. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol 2002;20:317-324. 4. Paulsen D, Reisaether A, Aasen M, Fauchald P. Use of tissue plasminogen activator for reopening of clotted dialysis catheters. Nephron 1993;64:468-70. 5. Blackwelder W. “Proving the null hypothesis” in clinical trials. Controlled Clin Trials 1982;3:345-53.